The comprehensive insights into the B-cells-mediated immune response against COVID-19 infection amid the ongoing evolution of SARS-CoV-2 - 20/03/25


Abstract |
The antibody-mediated immune response is crucial for the development of protective immunity against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Understanding the interaction between SARS-CoV-2 and the immune system is critical because new variants emerge as a result of the virus's ongoing evolution. Understanding the function of B cells in the SARS-CoV-2 infection process is critical for developing effective and long-lasting vaccines against this virus. Triggered by the innate immune response, B cells transform into memory B cells (MBCs). It is fascinating to observe how MBCs provide enduring immune defence, not only eradicating the infection but also safeguarding against future reinfection. If there is a lack of B cell activation or if the B cells are not functioning properly, it can lead to a serious manifestation of the disease and make immunisation less effective. Individuals with disruptions in the B cells have shown increased production of cytokines and chemokines, resulting in a poor prognosis for the disease. Therefore, we have developed an updated review article to gain insight into the involvement of B cells in SARS-CoV-2 infection. The discussion has covered the generation, functioning, and dynamics of neutralising antibodies (nAbs). Furthermore, we have emphasised immunotherapeutics that rely on nAbs.
Le texte complet de cet article est disponible en PDF.Highlights |
• | B cells play pivotal role in offering defense against viral infections. |
• | Perturbations in the B cells can lead to poor prognosis of the disease. |
• | Memory B cells (MBCs) play essential role in combatting the deleterious consequences of SARS-CoV-2’s variants. |
• | Neutralising antibodies (nAbs) generated by B cells have versatile applications in the development of therapeutic regimens against COVID-19. |
Keywords : COVID-19, Immune invasion, Immunotherapeutics, SARS-CoV-2, B-cells, Vaccines
Plan
Vol 185
Article 117936- avril 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?